TECHNESCAN MAG3 Drug Patent Profile

Which patents cover Technescan Mag3, and what generic alternatives are available?

Technescan Mag3 is a drug marketed by Curium and is included in one NDA.

The generic ingredient in TECHNESCAN MAG3 is technetium tc-99m mertiatide kit. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the technetium tc-99m mertiatide kit profile page.

Summary for TECHNESCAN MAG3

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	21
What excipients (inactive ingredients) are in TECHNESCAN MAG3?	TECHNESCAN MAG3 excipients list
DailyMed Link:	TECHNESCAN MAG3 at DailyMed

US Patents and Regulatory Information for TECHNESCAN MAG3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	TECHNESCAN MAG3	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	019882-001	Jun 15, 1990	AP	RX	Yes	Yes

Expired US Patents for TECHNESCAN MAG3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Curium	TECHNESCAN MAG3	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	019882-001	Jun 15, 1990	5,573,748

International Patents for TECHNESCAN MAG3

See the table below for patents covering TECHNESCAN MAG3 around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1292084	CHELATES MARQUES AU TECHNETIUM RADIOACTIF POUVANT ETRE UTILISES DANS LES ANALYSES DE LA FONCTION RENALE (RADIOLABELED TECHNETIUM CHELATES FOR USE IN RENAL FUNCTION DETERMINATIONS)
Japan	H05208986	RADIOACTIVITY-LABELLING TECHNETIUM CHELATE COMPOUND FOR MEASURING KIDNEY FUNCTION
Austria	60714
Japan	S6140295	RADIOACTIVE LABELED TECHNETIUMCHELATES FOR MEASURING KIDNEY FUNCTION
Japan	H0482159
Japan	H0749406

Supplementary Protection Certificates for TECHNESCAN MAG3

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

Market Dynamics and Financial Trajectory for Technescan MAG3

Last updated: July 29, 2025

---

Introduction

Technescan MAG3 (Mercaptoacetyltriglycine), a radiopharmaceutical agent, is primarily utilized in nuclear medicine imaging to evaluate renal function and morphology. Its distinctive capability to produce high-quality, dynamic renal scans positions it as a vital tool in diagnosing and managing renal pathologies. The global market dynamics for Technescan MAG3 are shaped by advancements in nuclear medicine, regulatory landscapes, rising prevalence of renal diseases, and technological innovations. Analyzing the financial trajectory of this drug provides insight into industry trends, investment risks, and growth opportunities.

---

Market Overview

Global Market Size

The global nuclear medicine imaging market, which incorporates Technescan MAG3, is projected to reach USD 4.5 billion by 2027, growing at a compound annual growth rate (CAGR) of roughly 5.2% from 2022[1]. Technescan MAG3 accounts for a significant share of renal imaging procedures, which themselves constitute a notable segment of nuclear medicine. The increasing adoption of renal scintigraphy in both developed and emerging markets fuels market expansion.

Key Market Drivers

• Rising Prevalence of Chronic Kidney Disease (CKD): The global burden of CKD is escalating, driven by diabetes, hypertension, and aging populations[2]. Accurate assessment of renal function has become critical, augmenting demand for Technescan MAG3 scans.

• Advancements in Nuclear Imaging: Enhanced imaging technology improves diagnostic accuracy, prompting increased utilization of radiopharmaceuticals like MAG3.

• Regulatory Approvals and Reimbursements: Favorable regulatory environments and reimbursements have historically spurred adoption in major markets such as North America and Europe.

• Growing Awareness and Access: Expanding healthcare infrastructure in Asia-Pacific facilitates broader access to nuclear medicine procedures, including MAG3 scans[3].

Market Limiters

• Stringent Regulations: Complex approval pathways for radiopharmaceuticals can delay or restrict market penetration.

• Cost Constraints: High costs associated with nuclear medicine procedures may limit utilization, especially in resource-limited settings.

• Availability of Alternative Technologies: Non-radioactive imaging modalities offer competing diagnostic options, though with varying efficacy in renal assessments.

---

Competitive Landscape

Major pharmaceutical and diagnostics companies involved with Technescan MAG3 include Bracco Imaging, GE Healthcare, and Lantheus Medical Imaging. These firms focus on manufacturing, distributing, and innovating radiopharmaceuticals, with strategic collaborations aimed at expanding indications and markets.

Bracco Imaging, as the primary supplier of Technescan MAG3, holds a dominant position in the domestic and certain international markets. Its strategy involves expanding indications, optimizing manufacturing processes, and engaging in clinical research to sustain competitive advantages.

---

Regulatory and Reimbursement Environment

Regulatory approval for Technescan MAG3 in key territories involves compliance with agencies like the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency). Recent approvals have been bolstered by evidence demonstrating safety and diagnostic effectiveness.

Reimbursement policies vary by country but generally favor radiopharmaceuticals' inclusion owing to their cost-effectiveness and clinical utility. Reimbursement levels influence hospitals and clinics' willingness to adopt MAG3, directly impacting revenue forecasts.

---

Financial Trajectory Analysis

Revenue Trends

Historical revenues for Technescan MAG3 have demonstrated steady growth aligned with the broader nuclear medicine market expansion. Specifically, revenue growth rates have averaged approximately 4-6% annually over the past five years[4].

Profitability and Investment

Manufacturers benefit from high margins due to specialized manufacturing processes and limited competition. Monetization strategies include licensing, supply contracts, and clinical development collaborations.

Forecasted Growth

Analysts project a compounded growth rate of approximately 7% for Technescan MAG3 revenues through 2030, driven by factors including:

• Increased global renal disease incidence: Estimated to add 1.2 million new cases annually worldwide[2].
• Technological innovations: Enhanced imaging followed by broader indications are expected to boost demand.
• Market expansion: Entry into emerging markets and increased healthcare infrastructure investment amplify sales potential.

Risks and Challenges

Potential challenges include regulatory delays, manufacturing bottlenecks, and competition from emerging renal imaging agents such as PET-based radiotracers. Additionally, macroeconomic factors like healthcare policy reforms and pricing pressures could temper the profit trajectory.

---

Emerging Trends Influencing Market Dynamics

Personalized Medicine and Diagnostic Precision

Integration of MAG3 imaging with advanced data analytics and AI enhances diagnostic accuracy, opening opportunities for premium pricing and tailored therapies.

Innovation in Radiopharmaceuticals

Development of next-generation agents with longer half-lives and improved imaging properties could threaten Technescan MAG3's market share, prompting ongoing R&D investments.

Regulatory Evolution

Streamlining approval processes through initiatives like the FDA's Breakthrough Devices Program and EMA's adaptive pathways could accelerate market access, impacting financial forecasts positively.

---

Conclusion

The financial trajectory of Technescan MAG3 is poised for moderate but consistent growth through 2030. Its success hinges on demographic trends, technological progress, and regulatory adaptability. Strategic positioning, including ongoing clinical research and international expansion, remains essential for stakeholders aiming to capitalize on the drug's potential.

---

Key Takeaways

• The global nephro-imaging market, including Technescan MAG3, is projected to grow at approximately 5-7% annually, driven by escalating kidney disease prevalence.
• Innovation and technological enhancements will serve as catalysts for increased demand, while regulatory pathways remain critical success factors.
• Revenue growth is supported by high-margin production, strategic alliances, and expanding global access, though challenges like competition and costs persist.
• Entering emerging markets and leveraging advancements in personalized diagnostics can unlock new revenue streams.
• Continuous R&D and regulatory engagement are essential for maintaining competitive advantage and ensuring sustained financial performance.

---

FAQs

Q1: What are the primary clinical advantages of Technescan MAG3 over alternative renal imaging agents?
Technescan MAG3 offers high-quality, dynamic renal imaging with excellent extraction and clearance profiles, allowing precise functional assessment. Its favorable safety profile and widespread clinical familiarity further differentiate it from newer agents.

Q2: How does the regulatory environment impact the market dynamics of Technescan MAG3?
Regulatory approvals are pivotal; efficient approval processes facilitate quicker market access and revenue generation. Conversely, delays or restrictions can hinder growth, especially in emerging markets.

Q3: What are the key growth opportunities for Technescan MAG3 in the coming decade?
Expanding into emerging markets, integrating with advanced imaging modalities, and demonstrating clinical superiority through research are primary opportunities.

Q4: How might competitive innovations affect the financial prospects of Technescan MAG3?
Emergence of alternative agents—such as PET-based tracers—could reduce MAG3's market share. Continued innovation in radiopharmaceuticals is essential to retain competitiveness.

Q5: What strategies should stakeholders adopt to maximize profitability from Technescan MAG3?
Investing in clinical research, fostering global partnerships, optimizing manufacturing, and navigating regulatory pathways effectively will enhance financial returns.

---

References

[1] MarketsandMarkets. "Nuclear Medicine Imaging Market." 2022.

[2] Global Burden of Disease Study. "Chronic Kidney Disease Facts." 2021.

[3] WHO. "Healthcare Infrastructure and Diagnostics Access in Asia-Pacific." 2020.

[4] Company Financial Reports (Lantheus, Bracco). Various fiscal years.